Gilead Sciences, Inc. (GILD): Long-Term Debt
$24.94B
As of 2025-12-31
$26.25B
As of 2026-06-30
-0.4%
3-year compound annual growth
-4.5%
5-year compound annual growth
+1.2%
10-year compound annual growth
| Period ended | Long-Term Debt | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $24.94B | -6.6% | 2026-02-24, Balance as of period end |
| 2024-12-31 | $26.71B | +6.9% | 2026-02-24, Balance as of period end |
| 2023-12-31 | $24.99B | -1.0% | 2025-02-28, Balance as of period end |
| 2022-12-31 | $25.23B | -5.5% | 2024-02-23, Balance as of period end |
| 2021-12-31 | $26.70B | -15.0% | 2023-02-22, Balance as of period end |
| 2020-12-31 | $31.40B | n/a | 2022-02-23, Balance as of period end |
| No annual figure between 2015-12-31 and 2020-12-31. | |||
| 2015-12-31 | $22.18B | +78.8% | 2016-02-24, Balance as of period end |
| 2014-12-31 | $12.40B | +86.9% | 2016-02-24, Balance as of period end |
| 2013-12-31 | $6.64B | -19.3% | 2015-02-25, Balance as of period end |
| 2012-12-31 | $8.22B | +8.1% | 2014-02-25, Balance as of period end |
| 2011-12-31 | $7.61B | n/a | 2013-02-27, Balance as of period end |
Long-Term Debt at similar companies
| Company | Year ended | Long-Term Debt | Change YoY |
|---|---|---|---|
| Gilead Sciences, Inc. (GILD) | 2025-12-31 | $24.94B | -6.6% |
| Amgen Inc (AMGN) | 2025-12-31 | $54.60B | -9.1% |
| Biogen Inc. (BIIB) | 2025-12-31 | $6.29B | -0.1% |
| Qiagen N.V. (QGEN) | 2025-12-31 | $1.65B | +18.9% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $2.14B | +42.3% |
| Repligen Corp (RGEN) | 2025-12-31 | $542.21M | +3.2% |
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $72.14M | -0.3% |
| Tarsus Pharmaceuticals, Inc. (TARS) | 2025-12-31 | $72.44M | +0.8% |
| Adaptimmune Therapeutics PLC (ADAPY) | 2024-12-31 | $54.28M | n/a |
Compare GILD, AMGN, BIIB, QGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗